Tesamorelin
Tesamorelin Acetate
Overview
Tesamorelin is a synthetic GHRH analog that is FDA-approved for the treatment of HIV-associated lipodystrophy. It is the only GHRH peptide with full FDA approval for a specific medical condition. It is particularly effective at reducing visceral adipose tissue (VAT) without significantly affecting subcutaneous fat.
Mechanism of Action
Tesamorelin stimulates pituitary GH release by binding to GHRH receptors, specifically targeting visceral fat reduction through GH-mediated lipolysis. It has been shown to reduce trunk fat, improve lipid profiles (triglycerides), and decrease C-reactive protein levels. Its selective action on visceral fat distinguishes it from other GH-related peptides.
Dosage Information
Typical Dose
2 mg
Frequency
Once daily
Administration
Subcutaneous injection
Notes
FDA-approved dose is 2mg daily. Clinical trials showed significant visceral fat reduction within 26 weeks. Must be administered on empty stomach.
Potential Side Effects
Research References
Community Experiences
No experiences shared yet. Be the first!
Stacking Compatibility
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 2 mg
- Frequency
- Once daily
- References
- 2 studies